Presentation is loading. Please wait.

Presentation is loading. Please wait.

P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial  D. Ettinger, O. Arrieta, N. Karaseva,

Similar presentations


Presentation on theme: "P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial  D. Ettinger, O. Arrieta, N. Karaseva,"— Presentation transcript:

1 P Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial  D. Ettinger, O. Arrieta, N. Karaseva, G. Chang, A. Rittmeyer, Y. Huang, R. Cheng, R. Varea, H. Ostojic, G. Mi, K. Winfree, E. Alexandris, F. Chan-Diehl, F. Cappuzzo  Journal of Thoracic Oncology  Volume 12, Issue 11, Pages S1969-S1970 (November 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S1969-S1970DOI: (10.1016/j.jtho.2017.09.854)
Copyright © Terms and Conditions


Download ppt "P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial  D. Ettinger, O. Arrieta, N. Karaseva,"

Similar presentations


Ads by Google